# RMD Partners

RMD Partners is a Private Equity based in Yokohama-shi, Japan.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Yokohama-shi, Japan
- **Region:** Asia
- **Address:** Yokohama-shi, Japan
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** www.rmdp.co.jp

## Regulatory record

- **Reports private funds:** No

## About

RMD Partners is a Japan-based venture capital firm that manages the MDS Fund (Medical Development Support 1号投資事業有限責任組合), a healthcare fund focused on medical devices. The fund was established in 2021 and has invested in companies developing devices for urology, vascular, and cerebrovascular applications.

## Sectors

- Medical Devices
- Healthcare Services
- Digital Health

## Questions

### What is the investment strategy of RMD Partners' Medical Development Support Fund?

The fund targets seed and early-stage opportunities across medical devices, carve-outs, and venture companies within the broader healthcare sector. It provides capital alongside regulatory and manufacturing partnership services, with a particular focus on helping Japanese academic and clinical inventions reach commercialization. Disclosed investments include vascular, neurological, and urological device companies.

### Does RMD Partners make direct investments or fund commitments?

RMD Partners operates exclusively through its Medical Development Support Fund I, a direct investment vehicle. There is no public indication of fund-of-fund commitments; all disclosed positions represent direct equity investments into device and digital-health companies.

### Which investment stages does RMD Partners typically target?

The firm explicitly targets seed and early-stage projects, citing development projects, carve-outs, and venture companies as its primary categories. This spans pre-revenue prototyping through early commercialization within the medical-device lifecycle.

### Has RMD Partners realized any exits?

The firm disclosed that its portfolio company Neuroceuticals Okinawa, a medical-device development and manufacturing business, was successfully exited via M&A to Otsuka Pharmaceutical Factory. RMD Partners described it as Fund I's first realized return.

### Does RMD Partners co-invest with external parties or provide syndicated deal access?

No syndication or co-investment structures are publicly disclosed. The firm's materials emphasize direct sourcing — linking overseas device seeds with Japanese manufacturing partners — but do not describe club-deal or external-LP co-investment programs.

## Related profiles

- [R.M. Davis](https://altss.com/profile/r-m-davis)
- [RM Financial Services](https://altss.com/profile/rm-financial-services)

---

Last updated: 2026-07-10T10:57:52.000Z

Canonical page: https://altss.com/profile/rmd-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology